Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome), Semaglutide
About this trial
This is an interventional treatment trial for PCOS (Polycystic Ovary Syndrome) focused on measuring PCOS, semaglutide, obese, metabolic abnormality, fertility
Eligibility Criteria
Inclusion Criteria: Meet the PCOS diagnostic criteria (Rotterdam) Age 22-40 BMI ≥ 28 kg/m2 Infertility: having normal sexual life and failing to conceive without contraception for more than 1 year Willing to be pregnant, and her husband has no serious infertility Exclusion Criteria: History of acute pancreatitis, individual or family history of medullary thyroid cancer and multiple endocrine adenomas Type 1 diabetes and special type diabetes History of tumor Serious cardiovascular and cerebrovascular disease, mental disease, liver or kidney disease Metformin, GLP-1 RA and other drugs affecting reproductive and metabolic functions were used within 90 days before the study Known allergy to metformin, GLP-1 RA and excipients Severe endometriosis, low ovarian reserve, premature ovarian failure Inability to tolerate pregnancy and ovulation induction therapy Other conditions considered unsuitable for this study by researchers
Sites / Locations
- PekingUFH
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
metformin
semaglutide
semaglutide and metformin
About 25 subjects will be allocated to this group to receive metformin only, as the active comparator of semaglutide groups. Metformin used in this trial is Glucophage ( 500mg per tablet)produced by Bristol-Myers Squibb.The initial dose of metformin will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
About 25 subjects will be allocated to this group to receive semaglutide only, as one of the experimental groups. Semaglutide used in this trial is WEGOVY (semaglutide) injection produced by Novo Nordisk. Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 1.0 mg is reached, and then maintained 1.0 mg until the end of treatment in total 12 weeks..
About 25 subjects will be allocated to this group to receive both semaglutide and metformin, as another of the experimental groups. Metformin used in this trial is Glucophage ( 500mg per tablet)produced by Bristol-Myers Squibb.The initial dose of metformin will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks. Semaglutide used in this trial is WEGOVY (semaglutide) injection produced by Novo Nordisk. Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals. Inject subcutaneously in the abdomen, thigh or upper arm. Initiate at 0.25 mg once weekly for 4 weeks. In 4 week intervals, increase the dose until a dose of 1.0 mg is reached, and then maintained 1.0 mg until the end of treatment in total 12 weeks.